The combination of disruptive technologies, a proven executive team, and a region ready to support and expedite pre-clinical and clinical development, uniquely positions Orion to rapidly and cost-effectively develop novel therapies for the treatment of severe eye diseases and get them into the clinic where patients desperately need therapeutic innovation.

Further, these platforms are broadly applicable; Our ORNx formulation technology can be used for virtually any drug that is poorly bioavailable—including NSAIDs, corticosteroids, kinase inhibitors, and antibiotics; and SAgAs for autoimmune diseases in which disease specific -antigens have been identified, such as neuromyelitis optica, Myasthenia Gravis and Juvenile Type 1 diabetes.

---

Soluble Antigen Arrays

Soluble Antigen Arrays (SAgAs)  are Orion's approach to providing a 'cure' to patients suffering from autoimmune disease. SAgAs act as an 'allergy shot' for autoimmunity as they provide a multivalent display of one or more disease specific antigen signals along a flexible polymer. This provides specific interaction with immune cells and promotes tolerance in patients suffering from diseases like MS, Graves, and Neuromyelitis optica.

ORNx Formlation

Orion's ORNx Formulation Technology enhances the availability of poorly water-soluble drugs by dramatically increasing dissolution kinetics while maintaining physical properties such as crystallinity, solubility, and stability. Our first clinical program looks to have a substantial and significant impact on the treatment of autoimmune associated uveitison, diabetic macular edema, and potentially chronic dry eye.